CA3064317A1 - Fgfr2 inhibitors for the treatment of cholangiocarcinoma - Google Patents
Fgfr2 inhibitors for the treatment of cholangiocarcinoma Download PDFInfo
- Publication number
- CA3064317A1 CA3064317A1 CA3064317A CA3064317A CA3064317A1 CA 3064317 A1 CA3064317 A1 CA 3064317A1 CA 3064317 A CA3064317 A CA 3064317A CA 3064317 A CA3064317 A CA 3064317A CA 3064317 A1 CA3064317 A1 CA 3064317A1
- Authority
- CA
- Canada
- Prior art keywords
- fgfr
- fgfr2
- patient
- inhibitor
- cholangiocarcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174295 | 2017-06-02 | ||
| EP17174295.0 | 2017-06-02 | ||
| EP18171315.7 | 2018-05-08 | ||
| EP18171315 | 2018-05-08 | ||
| PCT/EP2018/064523 WO2018220206A1 (en) | 2017-06-02 | 2018-06-01 | Fgfr2 inhibitors for the treatment of cholangiocarcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3064317A1 true CA3064317A1 (en) | 2018-12-06 |
Family
ID=62555054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3064317A Pending CA3064317A1 (en) | 2017-06-02 | 2018-06-01 | Fgfr2 inhibitors for the treatment of cholangiocarcinoma |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11707463B2 (https=) |
| EP (1) | EP3634414A1 (https=) |
| JP (2) | JP2020521794A (https=) |
| KR (1) | KR20200010505A (https=) |
| CN (1) | CN111050769A (https=) |
| AU (1) | AU2018278271B2 (https=) |
| BR (1) | BR112019025056A2 (https=) |
| CA (1) | CA3064317A1 (https=) |
| IL (1) | IL271058A (https=) |
| JO (1) | JOP20190280A1 (https=) |
| MA (1) | MA49248A (https=) |
| MX (1) | MX2019014366A (https=) |
| MY (1) | MY204203A (https=) |
| PH (1) | PH12019502710A1 (https=) |
| UA (1) | UA126478C2 (https=) |
| WO (1) | WO2018220206A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6752715B2 (ja) | 2014-03-26 | 2020-09-09 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 組合せ |
| TWI719960B (zh) | 2015-02-10 | 2021-03-01 | 英商阿斯迪克治療公司 | 新穎組成物 |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
| PH12021551949A1 (en) * | 2019-02-12 | 2022-07-18 | Janssen Pharmaceutica Nv | Cancer treatment |
| AU2020253827B2 (en) * | 2019-03-29 | 2026-01-08 | Janssen Pharmaceutica Nv | FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
| JP2022534742A (ja) * | 2019-05-28 | 2022-08-03 | キューイーディー セラピューティクス，インコーポレイテッド | 胆管癌を治療するための方法 |
| TW202114665A (zh) * | 2019-08-05 | 2021-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種吡咯并六員雜環化合物在製備治療ｆｇｆｒ２基因變異的腫瘤的藥物中的用途 |
| CN114945367A (zh) * | 2020-01-17 | 2022-08-26 | 贝达医药公司 | 作为fgfr激酶抑制剂的哒嗪和1,2,4-三嗪衍生物 |
| CN111596058A (zh) * | 2020-05-18 | 2020-08-28 | 山东第一医科大学(山东省医学科学院) | 一种检测胆管癌患者外周血循环肿瘤细胞fgfr基因突变的试剂盒及检测方法 |
| DE102021126650A1 (de) | 2021-10-14 | 2023-04-20 | Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts | Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff |
| KR20250117064A (ko) | 2024-01-26 | 2025-08-04 | 충북대학교 산학협력단 | 아무렌신 g를 유효성분으로 포함하는 담관암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| MX2007014782A (es) | 2005-05-23 | 2008-02-19 | Novartis Ag | Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona. |
| US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
| KR20100015883A (ko) * | 2007-03-23 | 2010-02-12 | 더 트랜스내셔날 게노믹스 리서치 인스티튜트 | 자궁내막암 및 전암을 진단，분류 및 치료하는 방법 |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| US9254288B2 (en) * | 2012-05-07 | 2016-02-09 | The Translational Genomics Research Institute | Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof |
| EP2945652B1 (en) * | 2013-01-18 | 2021-07-07 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| EP4063516A1 (en) | 2014-09-26 | 2022-09-28 | Janssen Pharmaceutica NV | Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2017
- 2017-06-16 JO JOP/2019/0280A patent/JOP20190280A1/ar unknown
-
2018
- 2018-06-01 AU AU2018278271A patent/AU2018278271B2/en not_active Ceased
- 2018-06-01 BR BR112019025056-5A patent/BR112019025056A2/pt not_active Application Discontinuation
- 2018-06-01 UA UAA201912271A patent/UA126478C2/uk unknown
- 2018-06-01 CN CN201880050198.0A patent/CN111050769A/zh active Pending
- 2018-06-01 MX MX2019014366A patent/MX2019014366A/es unknown
- 2018-06-01 WO PCT/EP2018/064523 patent/WO2018220206A1/en not_active Ceased
- 2018-06-01 MA MA049248A patent/MA49248A/fr unknown
- 2018-06-01 CA CA3064317A patent/CA3064317A1/en active Pending
- 2018-06-01 KR KR1020197038249A patent/KR20200010505A/ko not_active Ceased
- 2018-06-01 JP JP2019566178A patent/JP2020521794A/ja not_active Withdrawn
- 2018-06-01 MY MYPI2019007030A patent/MY204203A/en unknown
- 2018-06-01 EP EP18729631.4A patent/EP3634414A1/en active Pending
- 2018-06-01 US US16/616,067 patent/US11707463B2/en active Active
-
2019
- 2019-11-29 PH PH12019502710A patent/PH12019502710A1/en unknown
- 2019-12-01 IL IL271058A patent/IL271058A/en unknown
-
2023
- 2023-05-10 JP JP2023077882A patent/JP2023113650A/ja active Pending
- 2023-06-26 US US18/341,023 patent/US12350266B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200138809A1 (en) | 2020-05-07 |
| IL271058A (en) | 2020-01-30 |
| EP3634414A1 (en) | 2020-04-15 |
| US20240016801A1 (en) | 2024-01-18 |
| MX2019014366A (es) | 2020-07-27 |
| CN111050769A (zh) | 2020-04-21 |
| AU2018278271A1 (en) | 2019-12-05 |
| JP2023113650A (ja) | 2023-08-16 |
| JP2020521794A (ja) | 2020-07-27 |
| JOP20190280A1 (ar) | 2019-12-02 |
| MA49248A (fr) | 2020-04-15 |
| PH12019502710A1 (en) | 2020-06-08 |
| BR112019025056A2 (pt) | 2020-06-16 |
| KR20200010505A (ko) | 2020-01-30 |
| US11707463B2 (en) | 2023-07-25 |
| US12350266B2 (en) | 2025-07-08 |
| MY204203A (en) | 2024-08-15 |
| AU2018278271B2 (en) | 2024-07-04 |
| UA126478C2 (uk) | 2022-10-12 |
| WO2018220206A1 (en) | 2018-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12350266B2 (en) | FGFR2 inhibitors for the treatment of cholangiocarcinoma | |
| TWI816881B (zh) | 用於治療三陰性乳癌之組合療法 | |
| AU2024201871B2 (en) | Cancer treatment | |
| WO2018141921A1 (en) | Cancer treatment | |
| WO2020165181A1 (en) | Cancer treatment | |
| US12133851B2 (en) | Treatment of cholangiocarcinoma | |
| US20250000858A1 (en) | Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors | |
| JP7747521B2 (ja) | 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤 | |
| EA043608B1 (ru) | Ингибиторы fgfr2 для лечения холангиокарциномы | |
| HK40051490A (en) | Treatment of cholangiocarcinoma | |
| HK40029054A (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
| HK40103983A (en) | Cancer treatment | |
| HK40018978B (en) | Cancer treatment | |
| HK40018978A (en) | Cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220929 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241101 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241226 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241226 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241226 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D123 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIOR ART DISCLOSURE DETERMINED COMPLIANT Effective date: 20250130 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250130 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250130 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250130 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250409 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250801 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250805 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250913 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250913 |